Recombinant L-asparaginase

1. A method of treating a disease characterized by benefiting from asparagine depletion in a human subject, the method comprising intramuscularly administering to the human subject a pharmaceutical composition having a pH of about 7.0 and comprising:

(i) a recombinant L-asparaginase; and

(ii) trehalose,

wherein the recombinant L-asparaginase is a tetramer,

wherein the tetramer comprises four monomers,

wherein each monomer has an amino acid sequence comprising SEQ ID NO: 1,

wherein the recombinant L-asparaginase in the pharmaceutical composition demonstrates less than 5% aggregation, and

wherein the treatment results in asparagine depletion in the subject, thereby treating the disease.

2. The method according to claim 1 , wherein the recombinant L-asparaginase demonstrates less than 4% aggregation.

3. The method according to claim 1 , wherein the recombinant L-asparaginase demonstrates less than 1% aggregation.

4. The method according to claim 1 , wherein the recombinant L-asparaginase is recombinantly produced in Pseudomonas fluorescens.

5. The method according to claim 4 , wherein the recombinant L-asparaginase is administered every other day over a period of 5 consecutive days followed by a rest period of 2 consecutive days.

6. The method according to claim 1 , wherein the recombinant L-asparaginase is administered every 48 hours in an amount of 25 mg/m 2 for two weeks.

7. The method according to claim 1 , wherein the recombinant L-asparaginase is administered every other day over a period of 5 consecutive days followed by a rest period of 2 consecutive days.

8. The method according to claim 1 , wherein the recombinant L-asparaginase demonstrates less than 3% aggregation.

9. The method according to claim 1 , wherein the recombinant L-asparaginase is recombinantly produced in a host cell of the order Pseudomonadales.

10. The method according to claim 1 , wherein the pharmaceutical composition comprises about 6.4% of trehalose.

11. The method according to claim 1 , wherein the pharmaceutical composition further comprises sodium phosphate.

12. The method according to claim 1 , wherein the disease is acute lymphoblastic leukemia (ALL).

13. The method according to claim 1 , wherein the disease is lymphoblastic lymphoma (LBL).

14. The method according to claim 1 , wherein the disease is colon carcinoma, colon adenocarcinoma, or colorectal adenocarcinoma.

15. The method according to claim 1 , wherein the human subject has previously experienced silent inactivation of an E. coli -derived asparaginase.

16. The method according to claim 1 , wherein the human subject has previously experienced an allergic reaction to an E. coli -derived asparaginase.

17. The method according to claim 1 , wherein the human subject has a nadir serum asparaginase activity level of at least about 0.1 IU/mL following the administration.

18. The method of claim 1 , wherein the pharmaceutical composition further comprises sodium chloride and sodium phosphate.

19. A method of treating a disease characterized by benefiting from asparagine depletion in a human subject comprising intramuscularly administering to the human subject a dose regimen of a pharmaceutical composition having a pH of about 7.0 and comprising a recombinant L-asparaginase and trehalose,

wherein the recombinant L-asparaginase is a tetramer,

wherein the dose regimen of the pharmaceutical composition comprises a cycle,

wherein the cycle comprises a first dose, a second dose and a third dose,

wherein the first dose, the second dose, and the third dose each independently comprise about 25 mg/m 2 or 50 mg/m 2 of the recombinant L-asparaginase,

wherein the cycle is optionally repeatable, and

wherein the first dose, second dose, and third dose are administered about 48-72 hours apart.

20. The method according to claim 19 , wherein the pharmaceutical composition is administered three times a week.

21. The method according to claim 19 , wherein the pharmaceutical composition is administered for 2 weeks.

22. The method according to claim 19 , wherein the first dose and the second dose are each administered in an amount of about 25 mg/m 2 .

23. The method according to claim 19 , wherein the third dose is administered in an amount of about 50 mg/m 2 .

24. The method according to claim 19 , wherein the first dose is administered on Monday, the second dose is administered on a Wednesday, and the third dose is administered on a Friday of the same week.

25. The method according to claim 19 , wherein the recombinant L-asparaginase comprises SEQ ID NO:1.

26. The method according to claim 19 , wherein the disease is acute lymphoblastic leukemia (ALL).

27. The method according to claim 19 , wherein the disease is lymphoblastic lymphoma (LBL).

28. The method according to claim 19 , wherein the disease is colon carcinoma, colon adenocarcinoma, or colorectal adenocarcinoma.

29. The method of claim 19 , wherein the third dose is larger than the first dose and the second dose.

30. The method of claim 29 , wherein the cycle is repeated at least once, the first dose and the second dose are administered about 48 hours apart, the second and the third dose are administered about 48 hours apart, and the third dose is administered about 72 hours before the first dose of a subsequent cycle.

31. The method of claim 19 , wherein the dose regimen comprises about 25 mg/m 2 of the recombinant L-asparaginase.

32. The method of claim 19 , wherein the pharmaceutical composition further comprises sodium chloride and sodium phosphate.